Search Results
Sep 10, 2026, 08:10 ET Consano Bio Announces Peer-Reviewed Publication Supporting the Therapeutic Potential of C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic Sciatica
chronic sciatica despite its prevalence and widespread societal and economic impact.About C‑1101C‑1101 is Consano Bio's lead investigational clinical candidate and the first pharmaceutical therapy of its kind in development: a novel, platelet-derived multi-protein biologic
More news about: Consano Bio
Sep 09, 2026, 09:00 ET Tiltify Launches the Creator Impact Honors to Recognize the Impact of Creator Giving
place during the finalist period.The full Creator Impact Class of 2026 will be announced October 27th.Full category descriptions, jury bios and the nomination form are available at
More news about: Tiltify
Sep 08, 2026, 09:00 ET Rose BioSolutions Appoints David Enloe as Chief Executive Officer
Biotech and Pharma Services Pioneer to Advance Rose Bio's Differentiated End-to-End PlatformROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- Rose BioSolutions ("Rose Bio"), a leading provider
More news about: Rose BioSolutions
Sep 08, 2026, 08:17 ET HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
clinically validated molecular pathways, with the goal of improving clinical outcomes while reducing treatment burden through less frequent dosing. Windward Bio's lead program is WIN378, a novel fully human monoclonal antibody engineered for improved potency, extended half-life and silenced effector function,
More news about: Harbour BioMed
Sep 08, 2026, 08:00 ET Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
clinically validated molecular pathways, with the goal of improving clinical outcomes while reducing treatment burden through less frequent dosing. Windward Bio's lead program is WIN378, a novel fully human monoclonal antibody engineered for improved potency, extended half-life and silenced effector function,
More news about: Kelun-Biotech
Sep 08, 2026, 03:00 ET Ribbon Bio Appoints Jay Therrien as Chief Business Officer
markets. As Chief Business Officer, Therrien will lead Ribbon Bio's efforts to expand adoption of its cell-free DNA solutions, with immediate focus on the company's recently launched MiroMine™ kit, which enables customers to access Ribbon Bio's powerful assembly algorithms and cell-free synthesis processes
More news about: Ribbon Bio
Sep 07, 2026, 08:00 ET Ministry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio
authorities, 16 meetings between 9 domestic companies and overseas regulatory authorities, and 2 meetings between overseas companies and MFDS — supporting K-Bio's entry into the global market and expanding the cooperative network among regulatory authorities.[Innovation] Accelerating the Great Leap
More news about: The Korea Herald
Sep 02, 2026, 10:12 ET My Adult Doctor™ Launches Nationwide Virtual Healthcare Platform Expanding 24/7 Urgent Care, Primary Care, Wellness, and Advanced Digital and AI Health Services Across All 50 States, Puerto Rico, and Guam
care, wherever they happen to walk through the door."By combining QC Healthcare's nationwide virtual healthcare infrastructure with Massive Bio's oncology-focused technology capabilities, the organizations aim to create improved pathways for patient education, navigation, and access."Clinical
More news about: QC Healthcare
Sep 02, 2026, 08:30 ET Halozyme to Participate at Upcoming Investor Conferences
settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE®
More news about: Halozyme Therapeutics, Inc.
Sep 02, 2026, 07:15 ET Transpire Bio to Participate in Upcoming Healthcare Investor Conferences During September
technology platforms, including dry powder inhalers and soft mist inhalers which enable its advancing pipeline of innovative inhalation medicines. Transpire Bio's pipeline includes innovative inhalation medicines for Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Pulmonary Arterial
More news about: Transpire Bio
Sep 01, 2026, 06:59 ET Q32 Bio to Participate in Upcoming September Investor Conferences
Time: 11:30 a.m. E.T.Location: New York, NYA webcast of each presentation will be available on the Events and Presentations page of Q32 Bio's website at
More news about: Q32 Bio
Aug 28, 2026, 10:30 ET Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery
ecosystem-based collaboration models, the platform aims to accelerate the global development and commercialization of innovative drugs, in line with Sanyou Bio's mission: "To make it easy to develop new drugs worldwide."Clicklinks: An Open and Collaborative Network EcosystemClicklinks
More news about: Sanyou Bio
Aug 27, 2026, 10:04 ET Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
the first patients in the Phase II SIRIUS study in COPD.Note: HBM9378 is known as SKB378 in Kelun-Biotech's pipeline and WIN378 in Windward Bio's pipeline.Porustobart (HBM4003) is a next-generation, fully human heavy-chain-only anti-CTLA-4 antibody discovered and developed using
More news about: Harbour BioMed
Aug 27, 2026, 09:00 ET Rose BioSolutions Appoints Thomas VanCott, Ph.D., as Head of HemaCare
and cellular materials across the cell and gene therapy space, today announced the appointment of Thomas VanCott, Ph.D., as Head of HemaCare, Rose Bio's Cell Solutions business.
More news about: Rose BioSolutions
Aug 26, 2026, 20:46 ET Top Leisure Travel Agencies Betting on Growth in 2027
Marketing and communications is the leading application, selected by 86%, while 73% expect employees and independent contractors to use AI for agent bios. Agencies are also applying AI to customer service, data analysis, revenue management and fraud detection.At the same time, respondents
More news about: Travel Leaders Network
Aug 26, 2026, 08:02 ET Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies.
More news about: Sino Biological
Aug 26, 2026, 08:00 ET Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies.
More news about: Monod Bio
Aug 20, 2026, 19:10 ET Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
advanced hepatocellular carcinoma (HCC). This milestone represents the first clinical evaluation of an RNA-based therapeutic originating from Brii Bio's internal discovery efforts. While BRII-5395 is an mRNA therapeutic vaccine, the Company's broader RNA platforms encompass multiple RNA modalities. During
More news about: Brii Biosciences Limited
Aug 20, 2026, 13:34 ET Folger Theatre Announces the Cast for Shakespeare's Measure for Measure
Association**Member of Stage Directors and Choreographers Society, Actors' Equity AssociationAll other creative team bios and headshots are available at:
More news about: Folger Shakespeare Library
Aug 20, 2026, 09:00 ET Benchling Brings Chemistry and Biology Together on One R&D Platform, Adds Chemistry Reactions and Predictive Models
Inductive Bio's ADMET prediction models enable any chemist using Benchling to predict the chemical and pharmacokinetic properties that determine whether a molecule can become a viable drug. Inductive Bio's models are independently validated by three consecutive
More news about: Benchling
Aug 20, 2026, 09:00 ET Health Union Announces Winners of the 2026 Social Health Awards: Celebrating the Voices Reshaping Healthcare From the Inside Out
year, and we are honored to make sure the important work of Health Leaders is seen and celebrated."The 2026 Social Health Awards winners, whose bios and accomplishments can be viewed on the
More news about: Health Union
Aug 19, 2026, 08:36 ET BlueFaucet Launches Autonomous AI Agent CRM for Solopreneurs and Small Merchants
partnerships and investment to accelerate market adoption.A press kit — including high-resolution product screenshots, demo videos and executive bios — is available on request.Get started: Solopreneurs and small merchants can create a free account and start their 30-day free trial today
More news about: BlueFaucet Inc.
Aug 18, 2026, 16:01 ET Halozyme Appoints Dannielle Appelhans to its Board of Directors
settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE® by
More news about: Halozyme Therapeutics, Inc.
Aug 18, 2026, 15:44 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
and biologics for an aggregate cash consideration of ₹76 crore INR, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL. Finalized on August 18, 2026, the acquisition marks a major step forward in PPL's long-range plan
More news about: Piramal Pharma Solutions
Aug 18, 2026, 15:36 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
and biologics for an aggregate cash consideration of ₹76 crore INR, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL. Finalized on August 18, 2026, the acquisition marks a major step forward in PPL's long-range plan
More news about: Piramal Pharma Solutions